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Abstract 1 
Background – Connective tissue disease (CTD) associated interstitial lung disease (ILD) often fails to 2 
respond to conventional immunomodulatory agents.  There is now considerable interest in the use of 3 
Rituximab in systemic autoimmune CTD, in patients refractory to standard treatments.    4 
Objectives - To review the experience of North Bristol NHS Trust managing patients with CTD-associated 5 
ILD with Rituximab and explore possible associations with treatment response. 6 
Methods – We conducted a retrospective analysis of all patients who received Rituximab under the Bristol 7 
CTD-ILD service, having failed to respond to other immunomodulatory treatments.  Results were collated 8 
for pulmonary function and radiological outcomes before and after treatment. 9 
Results – 24 patients were treated with Rituximab.  Their physiological parameters had failed to improve 10 
despite other immunomodulatory agents with a mean change in FVC prior to therapy of -3.3% (95% CI, -5.6 11 
to -1.1%) and mean DLCO change of -4.3% (95% CI, -7.7 to -0.9%).  After Rituximab, radiology remained 12 
stable or improved for 11, while worsening was observed in 9 patients.  The decline in FVC was halted 13 
following treatment, with a mean change of +4.1% (95% CI, 0.9 to 7.2%), while DLCO was stable (mean 14 
change +2.1% (95% CI, -1.0 to 5.2%).  Patients with myositis-overlap or anti-synthetase syndrome appeared 15 
to respond well to treatment, with 4 patients showing clinically significant improvement in FVC >10%. 16 
Conclusions – Rituximab is a therapeutic option in treatment refractory CTD-associated ILD.  Some disease 17 
subgroups may respond better than others, however more work is needed to define its role in managing 18 
these patients. 19 
  20 
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Rituximab in autoimmune connective tissue disease-associated interstitial lung disease 1 
Introduction 2 
An increased understanding of the molecular pathways of inflammation and autoimmunity has led to the 3 
development of targeted biological agents and expanded the repertoire of treatment options in the 4 
autoimmune connective tissue diseases (CTDs).  Lymphocyte-targeted therapies, including the anti-CD20 B-5 
cell depleting monoclonal antibody, Rituximab are now used in clinical practice for diseases such as 6 
rheumatoid arthritis, systemic lupus erythematous (SLE) and refractory anti-neutrophil cytoplasmic 7 
antibody-associated (ANCA) vasculitis (1-3). This has led to exploration of its use in CTD-associated 8 
interstitial lung diseases (ILD) in patients deteriorating despite other immunosuppressive therapy.  9 
Evidence for this approach is based on institutional experiences, with no randomised, controlled trials yet 10 
published. 11 
The CTDs are heterogeneous processes characterised by autoimmune-mediated inflammation targeting 12 
various organ systems with resultant end-organ damage (4).  A more detailed description of CTDs is 13 
beyond the scope of this introduction, readers are directed to the cited reviews (4, 5).  One mechanism of 14 
action of Rituximab is thought to be through depletion of CD20 positive B-lymphocytes, thereby inhibiting 15 
their differentiation into antibody producing cells and T-cell co-stimulation. Translational studies have 16 
highlighted other mechanisms, which are being further investigated (6).   17 
It is recognised that all patients with CTDs are at risk of ILD, some more so than others (5).  While this ILD 18 
may be subclinical, having been identified through both radiological appearances and lung function 19 
abnormalities in 33-57% of CTD patients with no respiratory symptoms (7-10), 5-80% of patients go on to 20 
develop clinically significant lung disease within 3 years, with variation depending on the specific CTD.  The 21 
radiological and histological pattern of ILD described varies depending on the underlying CTD 22 
(Supplementary Table S1), reflecting the heterogeneity of these conditions.   23 
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The Bristol Interstitial Lung Disease service runs a combined service with the Rheumatology CTD team to 1 
manage patients with progressive lung disease and over the last 5 years has developed extensive 2 
experience managing these patients with immunosuppression; typically including oral immunomodulatory 3 
agents, intravenous (IV) Methylprednisolone and IV Cyclophosphamide.  The aims of management in this 4 
population of patients are, where possible, to reverse disease progression and decisions to initiate B-cell 5 
depletion with Rituximab are implemented through a defined pathway.  These decisions are based on a 6 
combination of clinical or radiological deterioration, or attenuation of a previous improvement with 7 
immunomodulatory treatment.  This is a report of our experience. 8 
 9 
Methods and materials 10 
Patient selection 11 
Review of our clinical database identified twenty four patients managed in the combined ILD-12 
Rheumatology / CTD clinic treated with Rituximab.  Diagnosis of diffuse parenchymal lung disease was in 13 
accordance with British Thoracic Society Interstitial Lung Disease guidelines (11), with biopsies used where 14 
clinically indicated.  CTDs were diagnosed based on accepted international criteria.  A subgroup of patients 15 
were identified with myositis or the anti-synthetase syndrome for separate analysis.  Patients with 16 
Rheumatoid arthritis were excluded due to the distinct pattern of ILD observed in this group. 17 
Hospital records were reviewed to identify, pulmonary function tests (PFT) performed 5 to 7 months prior 18 
to Rituximab, in the 4 weeks immediately before treatment and 6 to 12 months following treatment.  19 
Where relevant, the same approach was taken to PFTs prior to, at treatment with and following 20 
cyclophosphamide therapy.  High resolution computed tomograms (HRCT) of the chest were identified 21 
from time of treatment and during follow-up.  Patients were followed for a median of 29.6 months (16.7).  22 
All PFT measurements were performed within the same respiratory physiology laboratory.   23 
This clinical review was performed with full ethical approval (Reference 15/EE/0023). 24 
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Imaging 1 
HRCTs were performed for clinical reasons.  Images were reconstructed on a standard HRCT algorithm and 2 
interspaced 1mm slices reviewed on lung window settings were assessed on two separate occasions, 6 3 
months apart, by an experienced ILD Thoracic Radiologist blinded to treatment and therapy.  Overall 4 
extent of interstitial pathology, in addition to the ground glass component, was evaluated and quantified 5 
according to the visual estimation of extent of involvement described by Oda et al (12).  Change, compared 6 
with baseline imaging, after treatment was assessed and categorised as: improved, stable or worsened.  7 
The κ value for intra-rater agreement for extent of disease was 0.55, with a value of 0.92 for interval 8 
change. 9 
Statistical analysis 10 
Values are shown as mean with standard deviation (SD), mean difference with confidence intervals or 11 
frequencies as appropriate.  Changes in PFTs and radiological extent are expressed as percentage change 12 
from start of therapy.  Changes in values before, at the time of, and after treatment were assessed for 13 
normality and analysed with one-sample t-test using a test value of 0 or paired t-test as appropriate.  14 
Categorical variables were analysed using Chi-square testing.  All analyses used a p-value of <0.05 as the 15 
threshold for statistical significance.  Analyses were performed using SPSS software (v21.0.0; IBM Corp.; 16 
Armonk, NY, USA). 17 
Results 18 
 19 
Twenty four patients (16 female), with a mean age of 51.4 years (SD 14.9), were treated with Rituximab 20 
between October 2009 and January 2015.  12 out of 24 patients were former smokers. The mean duration 21 
of follow-up after treatment was 29.6 months (16.7). Biopsy had been performed in a total of 11 patients.  22 
Patient characteristics are shown in Table 1. 23 
 24 
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These patients were all managed under the Bristol CTD-ILD service and all had a diagnosis of CTD-ILD. 1 
Twenty two patients had positive serology for autoimmune markers (Supplementary Table S2).  The 2 
diagnoses were reached through correlation of clinical, serological, radiological and histopathological data, 3 
with diagnoses confirmed through consensus in a multidisciplinary team (MDT) CTD-ILD forum involving 4 
Clinicians, Radiologists and Pathologists.  5 
 6 
Pre-Rituximab Disease course and treatment  7 
  8 
Following MDT review, it was concluded that all patients had failed to respond adequately to prior 9 
immunosuppressive therapies, including induction with pulsed intravenous Cyclophosphamide in 16 10 
patients (at a dose of 15mg/kg, capped at 1 gram, for 6 cycles, at 3 week intervals) with IV 11 
methylprednisolone (500mg-1g prior to each dose of Cyclophosphamide) and Mycophenolate mofetil in 10 12 
patients.  Details of the treatments given and the interval to rituximab are given in Supplementary Table 13 
S3.   14 
 15 
Prior to Rituximab, mean change in FVC was -3.3% (p=0.005, 95% CI, -5.6 to -1.1%), with mean DLCO change 16 
of -4.3% (p=0.02, 95% CI, -7.7 to -0.9%).  Of those treated with Cyclophosphamide, this did not reverse 17 
disease trajectory; mean change in FVC following pulsed intravenous treatment was -1.2% (p=0.51, 95% CI, 18 
-5.2 to +2.7%), mean change in DLCO was +1.3% (p=0.54, 95% CI, -3.1 to +5.7%) (Figure 1). 19 
 20 
CTs were available for review for all patients prior to treatment. On HRCT, mean disease extent was 40.8% 21 
(SD 20.3%) of the lung, with ground glass change representing a mean 55.6% (SD 36.3%) of affected areas.  22 
The radiological patterns for each patient are shown in Supplementary Table S4.  Twenty one patients had 23 
more than one CT available, enabling assessment of interval change prior to treatment.  Radiological 24 
appearances were deteriorating for 8 patients and had failed to improve for 11 patients.  For the two 25 
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patients whose imaging had improved, the MDT assessment was that there was further scope for 1 
improvement. 2 
 3 
Decision to treat 4 
 5 
The decision to commence Rituximab treatment was based on MDT discussion taking in to account clinical  6 
features including: 7 
 Progression or lack of improvement in rheumatological features 8 
and/or 9 
 Progressive lung function decline 10 
 and/orRadiological HRCT changes; either progressive changes or a failure of disease adjudged as 11 
reversible to improve or resolve (for example ground glass changes) 12 
 13 
Rituximab administration 14 
 15 
Rituximab was administered according to rheumatology/CTD protocol, at a dose of 1 gram intravenously 16 
infused at days 0 and 14.  Following treatment, oral immunosuppression was continued in all patients.   17 
 18 
Post-treatment disease course 19 
Pulmonary function testing data both before and after treatment were available for all patients.  FVC 20 
improved following treatment, with a mean change of 4.1% (p=0.01, 95% CI, 0.9 to 7.2%).  DLCO remained 21 
stable with a mean change of 2.1% (p=0.18, 95% CI, -1.0 to 5.2%).  Four patients demonstrated clinically 22 
meaningful improvements of >10% in their FVC following treatment (Figure 1).  When comparing pre- and 23 
post-treatment disease trajectory, Rituximab reversed previous trends in lung function change for both 24 
FVC (p=0.001) and DLCO (p=0.02). 25 
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 1 
HRCT imaging following treatment was available for 22 patients.  One patient died before interval imaging 2 
was completed and one patient with myositis-related lung disease has insufficient followup to merit 3 
interval imaging.  The mean change in disease extent was -3.75% (p=0.33, 95% CI -11.6 to 4.1).  By 4 
radiological criteria, the imaging had deteriorated for 9/22 patients, with 13/22 showing disease stability or 5 
improvement following treatment.  Chi-square analysis comparing the trend in radiological appearances 6 
before and after treatment demonstrated no significant differences (χ2 5.695, p=0.223). 7 
 8 
CTD-myositis overlap and anti-synthetase subgroup  9 
Thirteen patients (9 female) were identified from their clinico-serological phenotype with myositis or the 10 
anti-synthetase syndrome, with a mean age of 53.5 yrs (SD 13.2).  Seven of these were former smokers.  11 
They had physiological impairment at baseline with a mean FVC of 75.3% predicted (SD 17.0%) and mean 12 
DLCO 55.9% predicted (SD 16.4%).  On initial HRCT imaging, mean extent of disease was 37.3% (SD 19.2%) 13 
with ground glass representing 52.7% (SD 34.4%) of this disease.  Other treatments prior to Rituximab did 14 
not arrest deterioration in clinical and / or physiological parameters.  These trends were not significantly 15 
different to those with other diagnoses. 16 
 17 
Following treatment, FVC and DLCO both improved statistically by a significantly greater extent than in 18 
those patients with alternative diagnoses (Figure 2).  Four patients in the myositis overlap group 19 
demonstrated improvement in their FVC >10%, showing a clinically meaningful improvement.  Radiological 20 
appearances were assessed as improved in 3 out of 11 patients, with worsening of disease only adjudged 21 
in one patient (Table 2).  22 
 23 
When comparing patients with myositis or anti-synthetase syndrome with the remaining group, there were 24 
significant differences in the response to treatment.  FVC change after treatment was greater in the 25 
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myositis sub-group (p=0.002), as was improvement in DLCO (p=0.009) (Table 2).  There were no other 1 
significant between group differences.  The four patients in whom no autoantibody was identified 2 
demonstrated post-treatment deterioration (Figure 1, patients 17, 19, 22 and 23). 3 
 4 
Adverse events 5 
There were no complications observed associated with treatment.  One patient died due to disease 6 
progression four months after treatment.  7 
 8 
Discussion 9 
We report here our experience of Rituximab in CTD-ILD in a significant number of patients, including an 10 
identified cohort with CTD-myositis/overlap syndromes.  This report adds to limited published data for use 11 
of B-cell depletion as treatment in this difficult disease group.   12 
The decision to treat is multi-factorial, guided by a combination of respiratory parameters and also 13 
rheumatological considerations.  One unanswered question, and one that will prove challenging in the 14 
context of clinical trials, is the means of defining treatment success.  In some patients the aim of treatment 15 
is to arrest or slow decline, whilst in others the aim is to reverse disease.  In patients with CTD-ILD, namely 16 
SSc and overlap myositis, one could debate that disease stability or lack of progression is a marker of 17 
treatment response.  18 
Also a consideration is the natural history of disease.  Where endothelial injury has occurred, resulting in 19 
the beginnings of fibrosis, the mesenchymal cells within later fibroblastic foci may begin to drive 20 
progressive fibrosis.  Treatment aimed at arresting the autoimmune injury prior to this is the rationale 21 
behind aggressive treatment in early disease.  The clinical data for disease course and natural history of 22 
CTD-ILD is lacking however. 23 
 24 
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Our data demonstrates, consistent with previously published series, a numerical improvement in FVC, with 1 
stability of DLCO, however no impact was seen on radiological appearances.  It is important to highlight that 2 
these improvements were only clinically significant in four patients.  These “responders” were patients 3 
with myositis or anti-synthetase syndrome-related lung disease and this group appear to respond 4 
particularly well to treatment, with greater improvement in FVC and DLCO compared to the non-myositis 5 
group.  6 
The limitations to our data are their observational nature, and the heterogeneity of data captured in the 7 
course of disease.  Despite this, we have observed statistically significant benefit in these patients and 8 
clinically relevant benefit in a subgroup. 9 
Preliminary reports including case reports and series have suggested that B cell depletion is a potential 10 
therapeutic target in CTD-ILD. The first report of successful treatment of Systemic Sclerosis (SSc)-associated 11 
ILD with Rituximab was in 2008 (14), with further experience reported in a cohort of 8 patients, in whom 12 
the FVC and diffusing capacity of carbon monoxide (DLCO) increased significantly more than a matched 13 
cohort receiving standard treatment (15).  In addition, a further study has highlighted the potential role of 14 
Rituximab in the anti-synthetase syndrome; 11 patients with severe and progressive ILD, who had failed to 15 
improve with Cyclophosphamide, demonstrated stabilisation of their lung disease based on forced vital 16 
capacity (FVC), DLCO and high resolution computed tomography appearances (16). 17 
Keir and colleagues have reported their experience of Rituximab in a more diverse cohort of 50 patients 18 
with ILD of various aetiologies, including CTD-ILD and also hypersensitivity pneumonitis and smoking-19 
related ILDs (17).  They reported a median improvement in FVC in the 6-12 months following treatment of 20 
6.7%, with stability of DLCO.  The FVC in a subgroup of 33 patients with CTD-ILD, improved by 8.9%.  Their 21 
results suggested a role for anti-CD20 B cell therapies in CTD-ILD and possibly a wider role in other ILDs. 22 
A subset of CTD patients with inflammatory myositis have been recognised to have a high risk of ILD.  This 23 
group of diseases includes the anti-synthetase syndrome (ASS), which is characterised by auto-antibodies 24 
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against the aminoacyl-tRNA synthetases, including anti-Jo1, anti-PL7 and anti-PL12.  This clinical syndrome 1 
is characterised by prominent ILD, with in some accompanying myositis, cutaneous changes including 2 
“mechanic’s hands”, fevers and non-erosive arthritis (18).  A number of factors in this group have been 3 
linked with the development and severity of ILD, including Asian ethnicity, those with severe skin 4 
involvement, minimal or no clinical muscle weakness and pyrexia.  This group of patients may also manifest 5 
ILD as their first presentation of CTD.  In one cohort, 15% of new patients referred to a tertiary referral 6 
centre met diagnostic criteria for CTDs (19). 7 
Our observed response to Rituximab therapy in a myositis-overlap group complements the findings of the 8 
RIM study (20).  This large randomised, controlled trial of early (at weeks 0 and 1), compared to late (at 9 
weeks 8 and 9) Rituximab in treatment-refractory myositis found no difference in the primary end point of 10 
time to achieve the International Myositis Assessment and Clinical Studies Group preliminary definition of 11 
improvement. This is likely to have been due to study design, as 83% of patients had achieved the primary 12 
outcome by 20 weeks from randomisation.  Interestingly, those patients in whom no autoantibody was 13 
identified seemed to fail to respond to Rituximab in our cohort.  A subgroup analysis in the RIM study 14 
demonstrated that presence of anti-synthetase autoantibodies was a strong predictor of improvement 15 
with treatment (13). 16 
This adds to the weight of evidence of the heterogeneity of CTD-ILD, and also further underscores the need 17 
for further research in this group of patients for whom there is little robust evidence for treatment.  The 18 
RECITAL study, a randomised, controlled trial comparing Rituximab to Cyclophosphamide in CTD-ILD 19 
(clinicaltrials.gov identifier: NCT01862926) is designed to address this important question.  A further 20 
resource, which would be of value in this field by pooling data such as ours, would be a registry for CTD-21 
ILD. 22 
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Data such as ours remains central to providing evidence to support the decision to use agents such as 1 
Rituximab in these patients and in the absence of published clinical trials is vital to support decision 2 
making, including those surrounding clinical commissioning within NHS England. 3 
In conclusion, we present here our experience using Rituximab for treatment-refractory CTD-ILD.  4 
Rituximab appears to stabilise clinical, physiological and radiological features in this cohort, with particular 5 
benefit seen in a subgroup of patients with myositis-overlap syndromes.  The role of Rituximab in CTD-ILD 6 
is promising but remains to be defined and our data highlights the need for more research to identify those 7 
patients who will have the best response to treatment. 8 
Key messages 9 
 Rituximab appears to stabilise disease in patients with connective tissue disease-associated interstitial lung 10 
disease. 11 
 Patients with myositis-overlap syndromes, including the anti-synthetase syndrome appeared to respond well to 12 
Rituximab. 13 
 Further research is needed to identify which patient groups will benefit from Rituximab. 14 
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Figure Legends 42 
Figure 1 – Changes in lung function before and after treatment 43 
FVC – Forced vital capacity, DLCO – Diffusing capacity for carbon monoxide. *p=0.001, **p=0.02 44 
 45 
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Figure 2 – Comparison of myositis subgroup and other patients’ response to treatment 1 
FVC – Forced vital capacity, DLCO – Diffusing capacity for Carbon Monoxide. * p<0.01 2 
 3 
4 
16 
 
Tables 1 
Table 1 – Baseline characteristics of patients 2 
Demographics  
Age 51.4 (14.9) 
Female 16 (66.7%) 
Ex-smokers 12 (50%) 
Oxygen use 5/24 
Diagnosis  
Anti-synthetase syndrome (ASS) 10 
Dermatomyositis (other / non-ASS) 3 
Systemic sclerosis 3 
Sjögren’s syndrome 2 
SLE 2 
Unclassifiable CTD-ILD  4 
Biopsy 11/24 
Histopathological pattern  
NSIP 9 
LIP 1 
Hypersensitivity Pneumonitis 1 
Identified auto-antibodies (see 
Supplementary table S2) 
22/24 
Treatments  
Cyclophosphamide 16 
IV Methylprednisolone 16 
Mycophenolate mofetil 9 
Hydroxychloroquine 2 
Azathioprine 4 
Methotrexate 1 
Physiology  
FVC (% pred) 78.4 (21.4) 
FEV1 (% pred) 75.4 (18.6) 
FEV1/FVC ratio 0.81 (0.06) 
DLCO (% pred) 50.9 (18.0) 
SO2 (%) 96 (1.5) 
SLE – Systemic Lupus Erythematous, NSIP – Non-specific Interstitial Pneumonia, LIP – 
Lymphocytic Interstitial Pneumonia, FVC – Forced Vital Capacity, FEV1 – Forced Expiratory 
Volume in 1 second, DLCO – Diffusing Capacity for Carbon Monoxide, SO2 – Oxygen 
Saturations 
 3 
  4 
17 
 
Table 2 – Comparison of treatment effects in myositis and non-myositis group of patients 1 
 Myositis group Non-myositis group p-value 
Mean SD Mean SD 
FVC 
change 
(%) 
Before 
treatment 
-3.5 6.5 -3.1 3.7 0.84 
After 
treatment 
8.3 4.7 -0.9 7.3 0.002 
DLCO 
change 
(%) 
Before 
treatment 
-2.2 5.7 -6.8 10.0 0.19 
After 
treatment 
5.5 6.8 -2.0 5.9 0.009 
Change in disease extent 
on CT (%) 
-10.0 18.4 3.6 16.4 0.068 
FVC – Forced Vital Capacity, DLCO – Diffusing Capacity for Carbon Monoxide 
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Supplementary tables 1 
Table S1 – Incidence of subtypes of ILD in CTD 2 
 Patients 
with 
lung 
involve
ment 
UIP NSIP COP DAD LIP DAH 
Systemic sclerosis 20-65% ++ ++++ + + - - 
Rheumatoid 
arthritis 
~70% ++ + - + - - 
Mixed connective 
tissue disease 
20-80% ++ +++ - - + - 
Systemic lupus 
erythematosus 
50-60% + + + ++ - +++ 
Inflammatory 
myositis-CTD 
overlap* 
~75% ++ ++++ ++ + - - 
Primary Sjogren’s 
syndrome 
10-30% + + + - +++ - 
 (Lowest (-) to highest (++++)).   
UIP (Usual Interstitial Pneumonia), NSIP (Non-specific Interstitial Pneumonia), COP (Cryptogenic 
Organising Pneumonia), DAD (Diffuse Alveolar Damage), LIP (Lymphocytic Interstitial 
Pneumonia), DAH (Diffuse Alveolar Haemorrhage). 
*Includes Anti-synthetase syndrome, dermatomyositis and overlap myositis. 
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Table S2 – Patient diagnoses and autoimmune profiles 1 
Patient Age Gender Diagnosis Radiological 
pattern 
Histopathological 
pattern 
Antibodies 
1 40.2 Male Scleroderma NSIP Fibrotic NSIP Scl70 
2 61.0 Female Dermatomyositis NSIP/OP  Jo1 
3 67.6 Female Anti-synthetase NSIP  RNP, Jo1 
4 62.0 Male Anti-synthetase NSIP/OP 
Cellular/Fibrotic 
NSIP 
EJ 
5 37.7 Female Anti-synthetase NSIP  Jo1 
6 73.0 Male Dermatomyositis NSIP  PM-Scl 
7 49.1 Female Anti-synthetase NSIP/OP  Jo1 
8 59.5 Female Anti-synthetase NSIP/OP  PL-12 
9 68.4 Female SLE NSIP  dsDNA 
10 29.7 Female Dermatomyositis NSIP  MDA5 
11 25.3 Female Scleroderma NSIP Fibrotic NSIP Ro, Scl70 
12 40.7 Female SLE OP  dsDNA 
13 48.8 Female Anti-synthetase NSIP/OP  Jo1 
14 36.8 Female Sjogren’s syndrome LIP LIP Ro, La 
15 36.2 Female Anti-synthetase NSIP/OP Cellular NSIP PL-7 
16 21.0 Male Scleroderma NSIP Fibrotic NSIP Scl70 
17 51.8 Female 
Unclassifiable CTD-
ILD NSIP Fibrotic NSIP 
pANCA 
18 64.7 Female Anti-synthetase NSIP Fibrotic NSIP PM-Scl 
19 57.0 Female 
Unclassifiable CTD-
ILD LIP Fibrotic NSIP 
No antibody 
detected 
20 47.8 Male Anti-synthetase NSIP/OP Fibrotic NSIP PM-Scl 
21 58.8 Male Anti-synthetase NSIP  PL-12 
22 60.8 Male 
Unclassifiable CTD-
ILD Possible UIP  
No antibody 
detected 
23 68.3 Male 
Unclassifiable CTD-
ILD NSIP  
Non-specific 
ANA 
24 66.4 Female Sjogren’s syndrome NSIP 
Hypersenstitivity 
pneumonitis 
RNP, Sm, 
dsDNA 
NSIP – Non-specific Interstitial Pneumonia, LIP – Lymphocytic Interstitial Pneumonia, OP, organising 
pneumonia, SLE – Systemic Lupus Erythematous, CTD-ILD – Connective Tissue Disease-associated 
Interstitial Lung Disease 
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Table S3 – Patient treatment prior to Rituximab 1 
Patient Diagnosis Pre-Rituximab treatment Duration of 
treatment 
Comments 
1 Scleroderma None  
Patient presented in 
extremis and treated 
urgently 
2 Dermatomyositis 
Previous oral cyclophosphamide, then 
MMF* >2 years 
 
3 Anti-synthetase 
IV cyclophosphamide and 
methylprednisolone, then azathioprine* 12 months 
 
4 Anti-synthetase 
IV methylprednisolone and 
cyclophosphamide, then MMF* 10 months 
 
5 Anti-synthetase IV cyclophosphamide, then MMF* 24 months  
6 Dermatomyositis IV cyclophosphamide 6 months  
7 Anti-synthetase IV cyclophosphamide, then MMF* 9 months  
8 Anti-synthetase 
IV cyclophosphamide, then 
azathioprine*and hydroxychloroquine* 12 months 
 
9 SLE Hydroxychloroquine* >2 years 
Unable to tolerate 
cyclophosphamide 
10 Dermatomyositis IV cyclophosphamide 21 months  
11 Scleroderma 
IV cyclophosphamide, then MMF*, with 
previous hydroxychloroquine and 
methotrexate 13 months 
 
12 SLE MMF* and hydroxychloroquine* >2 years  
13 Anti-synthetase IV cyclophosphamide, then MMF* 9 months  
14 Sjogrens 
IV cyclophosphamide and 
methylprednisolone, then azathioprine* 
and hydroxychloroquine* 10 months 
 
15 Anti-synthetase IV cyclophosphamide 20 months  
16 Scleroderma IV cyclophosphamide, then MMF* 7 months  
17 Unclassifiable CTILD IV cyclophosphamide, then MMF* 11 months  
18 Anti-synthetase IV cyclophosphamide 12 months  
19 Unclassifiable CTILD Methotrexate* >2 years  
20 Anti-synthetase IV cyclophosphamide, then MMF* 12 months  
21 Anti-synthetase 
IV methylprednisolone, then oral 
cyclophosphamide 18 months 
 
22 Unclassifiable CTILD IV cyclophosphamide 9 months  
23 Unclassifiable CTILD Methotrexate* 10 months  
24 Sjogrens None  
Unable to tolerate 
cyclophosphamide 
The ongoing treatment at the time of Rituximab is indicated by *.  All patients had received varying doses of oral 
prednisolone.  Where no oral treatment is stated, prednisolone was ongoing. 
NSIP – Non-specific Interstitial Pneumonia, LIP – Lymphocytic Interstitial Pneumonia, OP, organising pneumonia, SLE – 
Systemic Lupus Erythematous, MMF – Mycophenolate mofetil, IV - intravenous 
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Table S4 – Radiological pattern, extent of disease and response to treatment 1 
Patient Pattern Disease 
Extent 
(%) 
Ground 
glass (% 
extent 
within 
fibrosis) 
Traction 
change 
Improvement
/worsening 
Change in 
extent 
after 
treatment 
(%) 
 1 Cellular 
NSIP 
70 100 None Worse 5 
 2 NSIP/OP 15 0 None No change 5 
 3 NSIP 25 75 Mild Better -10 
 4 NSIP/OP 40 20 Mild No change 0 
 5 NSIP 30 90 None Worse 0 
 6 NSIP 10 50 None No change 0 
 7 NSIP/OP 50 0 None No change 0 
 8 NSIP/OP 20 40 Mild No change 0 
 9 NSIP 70 50 Moderate Worse 10 
 10 NSIP 25 80 None No change 0 
 11 NSIP 75 80 None Worse 0 
 12 OP 15 0 None Worse 0 
 13 NSIP/OP 70 100 None Better -40 
 14 LIP 30 100 None Worse 20 
 15 NSIP/OP 45 40 None   
 16 NSIP 40 100 None Worse 15 
 17 NSIP 30 90 None Worse 10 
 18 NSIP 50 50 Mild   
 19 LIP 50 0 None No change 0 
 20 NSIP/OP 35 40 None No change 0 
 21 NSIP 70 100 None Better -40 
22 Possible 
UIP 
40 10 Moderate  -40 
23 NSIP 60 60 Mild Worse 20 
24 NSIP 15 60 Mild No change 0 
NSIP – Non-specific Interstitial Pneumonia, LIP – Lymphocytic Interstitial Pneumonia, OP, 
organising pneumonia, UIP – Usual Interstitial Pneumonia 
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